Literature DB >> 25875962

Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide.

Valentina Finessi1, Francesco Nicoli, Eleonora Gallerani, Fabio Sforza, Mariaconcetta Sicurella, Aurelio Cafaro, Antonella Caputo, Barbara Ensoli, Riccardo Gavioli.   

Abstract

The use of the Tat protein of HIV in vaccines against AIDS showed promising results in primate and human studies. To characterize the impact of the administration route on the induction of humoral responses at systemic and mucosal levels, we compared intradermal, intramuscular and mucosal immunizations with Tat and a Tat-derived peptide. Mice were immunized with the Tat protein by different routes and the titer and isotype of anti-Tat antibodies were assessed in serum and mucosal lavages. Intramuscular and intradermal administrations showed comparable immunogenicity, while the mucosal administration was unable to induce IgM in serum and IgG at mucosal sites but showed superior immunogenicity in terms of IgA induction. Anti-Tat antibodies were also obtained upon vaccination with the immunodominant Tat 1-20 peptide which was, however, less immunogenic than the whole Tat protein.

Entities:  

Keywords:  HIV; Tat; routes of administration; vaccine

Mesh:

Substances:

Year:  2015        PMID: 25875962      PMCID: PMC4514195          DOI: 10.1080/21645515.2015.1016676

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  40 in total

Review 1.  Mucosal immunity and vaccination against HIV.

Authors:  Thomas Lehner; Peter A Anton
Journal:  AIDS       Date:  2002       Impact factor: 4.177

Review 2.  A systematic review of intradermal influenza vaccines.

Authors:  Flora Young; Fawziah Marra
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

3.  HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region.

Authors:  H C Chang; F Samaniego; B C Nair; L Buonaguro; B Ensoli
Journal:  AIDS       Date:  1997-10       Impact factor: 4.177

4.  Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.

Authors:  A Cafaro; A Caputo; C Fracasso; M T Maggiorella; D Goletti; S Baroncelli; M Pace; L Sernicola; M L Koanga-Mogtomo; M Betti; A Borsetti; R Belli; L Akerblom; F Corrias; S Buttò; J Heeney; P Verani; F Titti; B Ensoli
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

5.  Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

Authors:  C A van Baalen; O Pontesilli; R C Huisman; A M Geretti; M R Klein; F de Wolf; F Miedema; R A Gruters; A D Osterhaus
Journal:  J Gen Virol       Date:  1997-08       Impact factor: 3.891

6.  Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application.

Authors:  Antonella Caputo; Egidio Brocca-Cofano; Arianna Castaldello; Rita De Michele; Giuseppe Altavilla; Marco Marchisio; Riccardo Gavioli; Ulrika Rolen; Laura Chiarantini; Aurora Cerasi; Sabrina Dominici; Mauro Magnani; Aurelio Cafaro; Katia Sparnacci; Michele Laus; Luisa Tondelli; Barbara Ensoli
Journal:  Vaccine       Date:  2004-07-29       Impact factor: 3.641

7.  Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Authors:  Barbara Ensoli; Stefania Bellino; Antonella Tripiciano; Olimpia Longo; Vittorio Francavilla; Simone Marcotullio; Aurelio Cafaro; Orietta Picconi; Giovanni Paniccia; Arianna Scoglio; Angela Arancio; Cristina Ariola; Maria J Ruiz Alvarez; Massimo Campagna; Donato Scaramuzzi; Cristina Iori; Roberto Esposito; Cristina Mussini; Florio Ghinelli; Laura Sighinolfi; Guido Palamara; Alessandra Latini; Gioacchino Angarano; Nicoletta Ladisa; Fabrizio Soscia; Vito S Mercurio; Adriano Lazzarin; Giuseppe Tambussi; Raffaele Visintini; Francesco Mazzotta; Massimo Di Pietro; Massimo Galli; Stefano Rusconi; Giampiero Carosi; Carlo Torti; Giovanni Di Perri; Stefano Bonora; Fabrizio Ensoli; Enrico Garaci
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

Review 8.  HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.

Authors:  Antonella Caputo; Riccardo Gavioli; Stefania Bellino; Olimpia Longo; Antonella Tripiciano; Vittorio Francavilla; Cecilia Sgadari; Giovanni Paniccia; Fausto Titti; Aurelio Cafaro; Flavia Ferrantelli; Paolo Monini; Fabrizio Ensoli; Barbara Ensoli
Journal:  Int Rev Immunol       Date:  2009       Impact factor: 5.311

9.  Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.

Authors:  Antonella Caputo; Egidio Brocca-Cofano; Arianna Castaldello; Rebecca Voltan; Riccardo Gavioli; Indresh K Srivastava; Susan W Barnett; Aurelio Cafaro; Barbara Ensoli
Journal:  Vaccine       Date:  2008-01-15       Impact factor: 3.641

10.  The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses.

Authors:  Francesco Nicoli; Valentina Finessi; Mariaconcetta Sicurella; Lara Rizzotto; Eleonora Gallerani; Federica Destro; Aurelio Cafaro; Peggy Marconi; Antonella Caputo; Barbara Ensoli; Riccardo Gavioli
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more
  1 in total

1.  Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines.

Authors:  Francesco Nicoli; Salvatore Pacifico; Eleonora Gallerani; Erika Marzola; Valentina Albanese; Valentina Finessi; Sian Llewellyn-Lacey; David A Price; Victor Appay; Peggy Marconi; Remo Guerrini; Antonella Caputo; Riccardo Gavioli
Journal:  Vaccines (Basel)       Date:  2021-05-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.